These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 18596282

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM, Curry JA.
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract] [Full Text] [Related]

  • 23. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT.
    Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
    [No Abstract] [Full Text] [Related]

  • 24. Is having more preapproval data the best way to assure drug safety?
    Garber AM.
    Health Aff (Millwood); 2008; 27(5):w371-3. PubMed ID: 18682442
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The new Food and Drug Administration drug package insert: implications for patient safety and clinical care.
    Watson KT, Barash PG.
    Anesth Analg; 2009 Jan; 108(1):211-8. PubMed ID: 19095852
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned.
    Mathis LL, Iyasu S.
    Clin Pharmacol Ther; 2007 Aug; 82(2):133-4. PubMed ID: 17632537
    [Abstract] [Full Text] [Related]

  • 30. FDA Regulation of Prescription Drugs.
    Gassman AL, Nguyen CP, Joffe HV.
    N Engl J Med; 2017 Feb 16; 376(7):674-682. PubMed ID: 28199811
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Changes to US drug safety laws take center stage.
    Wadman M.
    Nat Med; 2007 Apr 16; 13(4):389. PubMed ID: 17415357
    [No Abstract] [Full Text] [Related]

  • 34. FDA advisory panel voices persistent safety concerns.
    Finkelstein JB.
    J Natl Cancer Inst; 2006 Apr 05; 98(7):439. PubMed ID: 16595778
    [No Abstract] [Full Text] [Related]

  • 35. Pharmacometrics at FDA: evolution and impact on decisions.
    Powell JR, Gobburu JV.
    Clin Pharmacol Ther; 2007 Jul 05; 82(1):97-102. PubMed ID: 17538553
    [Abstract] [Full Text] [Related]

  • 36. Xyrem (sodium oxybate) postmarketing adverse event reporting system.
    Wang YG.
    Sleep Med; 2010 Jun 05; 11(6):595; author reply 595-6. PubMed ID: 20362501
    [No Abstract] [Full Text] [Related]

  • 37. Report hits FDA to revamp safety oversight.
    Finkelstein JB.
    J Natl Cancer Inst; 2006 Jul 05; 98(13):884-5. PubMed ID: 16818849
    [No Abstract] [Full Text] [Related]

  • 38. Postmarketing surveillance for oncology drugs.
    Viale PH, Moore S.
    Clin J Oncol Nurs; 2008 Dec 05; 12(6):877-86. PubMed ID: 19064381
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Reform of drug regulation--beyond an independent drug-safety board.
    Ray WA, Stein CM.
    N Engl J Med; 2006 Jan 12; 354(2):194-201. PubMed ID: 16407517
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.